CMMB

Chemomab Therapeutics Ltd. NASDAQ Listed Feb 12, 2019

Healthcare ·Biotechnology ·IL · chemomab.com

$1.74

Mkt Cap $10.7M

52w Low $1.35 8.6% of range 52w High $5.88

50d MA $1.71 200d MA $2.43

P/E (TTM) -1.1x

EV/EBITDA -0.3x

P/B 0.8x

Debt/Equity 0.0x

ROE -72.9%

P/FCF -0.9x

RSI (14) —

ATR (14) —

Beta 0.58

50d MA $1.71

200d MA $2.43

Avg Volume 68.6K

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

SIC Code

2834

CIK (SEC)

1534248

Phone

972 77 331 0156

Building 7 · Tel Aviv 6158002 · IL

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 19, 2026	AMC	-0.20	-0.24	-20.0%	1.93	-1.6%	-7.8%	-5.6%	-6.5%	+1.3%	-2.5%	—
Nov 13, 2025	AMC	-0.20	-0.80	-300.0%	2.55	-1.2%	+4.3%	-2.3%	+5.0%	-1.1%	-10.0%	—
Aug 14, 2025	AMC	-0.80	-0.36	+55.0%	3.59	+0.8%	+3.6%	+1.1%	-1.1%	-1.3%	-3.5%	—
May 15, 2025	AMC	-0.20	-0.14	+30.0%	5.16	+0.0%	+6.2%	+1.5%	+0.0%	-0.7%	-1.4%	—
Mar 3, 2025	AMC	-0.20	-0.16	+20.0%	6.04	-5.3%	-13.9%	+7.7%	+5.7%	-15.5%	+4.0%	—
Nov 14, 2024	AMC	-0.20	-0.20	+0.0%	6.96	-2.9%	-4.0%	-1.2%	-1.8%	+1.2%	-2.4%	—
Aug 21, 2024	AMC	-0.20	-0.26	-30.0%	4.88	-2.5%	+0.0%	+14.8%	+12.9%	+4.4%	+12.7%	—
May 9, 2024	AMC	-0.20	-0.28	-40.0%	3.24	-2.5%	+3.7%	-3.0%	+8.0%	-0.9%	-0.3%	—
Mar 7, 2024	AMC	-0.40	-0.26	+35.0%	3.20	-5.9%	-3.1%	+6.5%	+4.2%	-4.1%	+0.6%	—
Nov 9, 2023	AMC	-0.60	-0.34	+43.3%	2.40	-0.8%	-1.7%	-6.8%	+10.9%	+34.0%	-19.3%	—
Aug 14, 2023	AMC	-0.80	-0.72	+10.0%	4.52	-6.2%	-0.9%	-4.5%	-1.9%	+3.8%	+0.0%	—
May 11, 2023	AMC	-0.80	-0.80	+0.0%	6.48	+1.2%	-2.5%	+3.2%	+1.2%	+9.1%	+2.2%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Aug 27	Oppenheimer	Maintains	Outperform → Outperform	—	$3.40	$3.40	+0.0%	+2.4%	-2.0%	-7.9%	-1.3%	-2.6%
May 16	Oppenheimer	Maintains	Outperform → Outperform	—	$5.16	$5.16	+0.0%	+6.2%	+1.5%	+0.0%	-0.7%	-1.4%
Feb 20	Maxim Group	Maintains	Buy → Buy	—	$7.60	$7.28	-4.2%	-6.8%	-3.4%	-1.8%	-7.7%	+5.2%
Nov 15	Oppenheimer	Maintains	Outperform → Outperform	—	$6.96	$6.76	-2.9%	-4.0%	-1.2%	-1.8%	+1.2%	-2.4%
May 6	Oppenheimer	Upgrade	Perform → Outperform	—	$2.96	$3.28	+10.8%	+15.2%	+4.4%	-18.5%	+11.7%	+3.7%
Mar 8	Oppenheimer	Maintains	Perform → Perform	—	$3.20	$3.01	-5.9%	-3.1%	+6.5%	+4.2%	-4.1%	+0.6%
Jun 7	Oppenheimer	Downgrade	Outperform → Perform	—	$6.88	$6.88	+0.0%	-1.2%	+2.9%	+0.0%	-1.1%	+2.3%
Apr 18	Oppenheimer	Maintains	Outperform → Outperform	—	$6.52	$6.52	+0.0%	+1.8%	+1.2%	-6.0%	+2.5%	-3.7%
Mar 10	Oppenheimer	Maintains	Outperform → Outperform	—	$15.16	$16.36	+7.9%	+7.9%	+2.7%	-5.5%	+0.0%	+5.5%
Dec 7	Aegis Capital	Maintains	Buy → Buy	—	$29.72	$31.76	+6.9%	+6.2%	+2.8%	-1.1%	-0.4%	-1.4%
May 26	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$64.28	$67.08	+4.4%	+4.9%	+0.9%	+4.0%	-3.6%	+2.1%
May 7	Oppenheimer	Maintains	Outperform → Outperform	—	$79.40	$92.00	+15.9%	-0.1%	-4.6%	-5.0%	-4.6%	-3.3%

Data updated apr 26, 2026 10:11am · Source: massive.com